Reckitt Benckiser plans to spin off its heroin-addiction treatment in the next 12 months as sales slide under pressure from rival versions.» Read More
A plan to automatically re-enroll the vast majority of people who bought health insurance on HealthCare.gov could lead to some nasty surprises.
A stunning one in 10 deaths in working-age adults may be due to excessive alcohol consumption, a new government study shows.
Obamacare has stirred a lot of partisan bickering but here's one thing you can't argue about, says Jake Novak.
The vast majority of people who enrolled in Obamacare on HealthCare.gov will be re-enrolled in their health plans and subsidies they receive.
The holiday season is a great time for getting gifts, but an awful time to enroll people in Obamacare, a new analysis finds.
The New York State Supreme Court ruled on Thursday that New York City's ban on big sodas, which was blocked by lower courts, is illegal.
The word "unexpectedly" for negative economic data has become a much-mocked cliché, but this week's first-quarter GDP number deserves an exception. The Fiscal Times reports.
Hedge fund Paulson & Co has amassed a large stake in Allergan and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals.
The U.S. Food and Drug Administration warned that popular acne products can cause rare but serious and life-threatening allergic reactions.
A crisis of GM proportions awaits the US if we don't fix some big problems like tax reform and Social Security, says Loews co-chair Andrew Tisch.
Most insurers in Florida aren't disclosing their Obamacare rates for next year because they say they are trade secrets.
The uninsured rate in the US has fallen due to Obamacare, but the wide ranges of rates in individual states could actually grow wider.
Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.
The British Medical Association voted on Tuesday in favor of a lifelong ban on cigarette sales to people born after 2000.
A longtime contraction in employer health-care spending is set to end in 2015 and resume an upward trend, according to a forecast.
A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.
A U.S. Senate panel asked the Centers for Disease Control and Prevention to explain the breach that exposed many to live anthrax, a deadly pathogen.
A government agency is claiming that the VA's own investigation of itself holds contradictions, CNBC has learned.
Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.
Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.
Get the best of CNBC in your inbox